Group 1 - The core announcement is that 194 products from the company have been included in the National Medical Insurance Directory for 2025, consisting of 92 Class A and 102 Class B products [1] - Notable inclusions are the injectable Aripiprazole microspheres, which are newly negotiated for inclusion, and the injectable Triptorelin acetate microspheres, which have a new indication added [1] - The company expects that the inclusion of these products will help expand market access and improve drug availability, positively impacting future operating performance [1] Group 2 - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1] - There are no products from the company that have exited the National Medical Insurance Directory [1]
丽珠医药集团股份有限公司关于公司产品纳入国家医保目录的公告